#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JANUARY 2023

**COMMISSION FILE NUMBER 001-38976** 

#### Genmab A/S

(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43 1560 Copenhagen V Denmark +45 70 20 27 28

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes 🗆 🛛 No 🖾

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes 🗆 🛛 No 🖾

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENMAB A/S

BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer

DATE: January 3, 2023

#### EXHIBIT INDEX

#### Exhibit Description of Exhibit

99.1 Company Announcement Dated January 3, 2023: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons



#### **Company Announcement**

COPENHAGEN, Denmark; January 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.


The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons.

This company announcement includes the partial vesting and net settlement of the restricted stock units granted to Jan van de Winkel and Judith Klimovsky on December 5, 2019. The remaining part of these two grants is subject to an additional vesting criteria and will vest upon confirmation thereof.

Please find below a statement of such trading in shares issued by Genmab A/S.


1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Jan G. J. van de Winkel	
2.	Reason for the notification		
a)	Position/status	President & Chief Executive Office	er
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo auction platform, auctioneer or au		
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): section		
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place		onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restric	cted stock units
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	5,277
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 1/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122




1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Judith Klimovsky	
2.	Reason for the notification	·	
a)	Position/status	Executive Vice President & Chief I	Development Officer
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	owance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): sect	on to be repeated for	
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place	where transactions have been co	onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restri	
C)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	3,385
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 2/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122




1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Anthony Pagano	
2.	Reason for the notification	•	
a)	Position/status	Executive Vice President & Chief F	-inancial Officer
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	wance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): secti	on to be repeated for	
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place	where transactions have been co	onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restric	cted stock units
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	1,100
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 3/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122




1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Tahamtan Ahmadi	
2.	Reason for the notification		
a)	Position/status	Executive Vice President & Chief M	Aedical Officer
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	wance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): section	on to be repeated for	
	(i) each type of instrument; (ii) eac	h type of transaction;	
	(iii) each date; and (iv) each place	where transactions have been co	nducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restric	ted stock units
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	1,309
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 4/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122




1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Deirdre P. Connelly	
2.	Reason for the notification		
a)	Position/status	Chair of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	• • •	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): section	on to be repeated for	
	(i) each type of instrument; (ii) eac	•	
	(iii) each date; and (iv) each place	where transactions have been co	onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restric	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	371
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 5/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Pernille Erenbjerg	
2.	Reason for the notification	•	
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	wance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): secti	•	
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place		onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restricted	ed stock units
C)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	247
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 6/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



1.	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	Anders Gersel Pedersen		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Dire	ectors	
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission a	llowance market participant,		
	auction platform, auctioneer or	auction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	529900MTJPDPE4MHJ122		
4.	Details of the transaction(s): see	ction to be repeated for		
	(i) each type of instrument; (ii) e	ach type of transaction;		
	(iii) each date; and (iv) each plac	ce where transactions have b	een conducted	
a)	Description of the financial	Share		
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Acquisition due to vesting of	restricted stock units	
C)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	247	
d)	Aggregated information			
	<ul> <li>Aggregated volume</li> </ul>			
	- Price			
e)	Date of the transaction	2023-01-02		
f)	Place of the transaction	Outside a market place	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 7/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122




1.	Details of the person discharging	Details of the person discharging managerial responsibilities /		
	person closely associated			
a)	Name	Martin Schultz		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Directors		
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission all	owance market participant,		
	auction platform, auctioneer or a	uction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	529900MTJPDPE4MHJ122		
4.	Details of the transaction(s): sect	•		
	(i) each type of instrument; (ii) ea			
	(iii) each date; and (iv) each place	where transactions have been co	onducted	
a)	Description of the financial	Share		
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction	Acquisition due to vesting of res Genmab A/S)	tricted stock units (as employee of	
C)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	175	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2022-01-03		
f)	Place of the transaction	Outside a market place		

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 8/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



1.	Details of the person discharging	Details of the person discharging managerial responsibilities /		
	person closely associated			
a)	Name	Mijke Zachariasse		
2.	Reason for the notification			
a)	Position/status	Member of the Board of Directors		
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission allo	owance market participant,		
	auction platform, auctioneer or au	ction monitor		
a)	Name	Genmab A/S		
b)	LEI-code	529900MTJPDPE4MHJ122		
4.	Details of the transaction(s): section	on to be repeated for		
	(i) each type of instrument; (ii) eac			
	(iii) each date; and (iv) each place	where transactions have been co	onducted	
a)	Description of the financial	Share		
	instrument, type of instrument			
	Identification code	DK0010272202		
b)	Nature of the transaction		cted stock units (partly as employee	
		of Genmab B.V., partly as board m	-	
C)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 0.00	175	
d)	Aggregated information			
	- Aggregated volume			
	- Price			
e)	Date of the transaction	2023-01-02		
f)	Place of the transaction	Outside a market place		

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 9/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Paolo Paoletti	
2.	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	owance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): secti	on to be repeated for	
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place	where transactions have been co	onducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restric	cted stock units
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	247
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 10/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



1.	Details of the person discharging managerial responsibilities /		
	person closely associated		
a)	Name	Rolf Hoffmann	
2.	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allo	wance market participant,	
	auction platform, auctioneer or au	ction monitor	
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
4.	Details of the transaction(s): section	on to be repeated for	
	(i) each type of instrument; (ii) eac		
	(iii) each date; and (iv) each place		nducted
a)	Description of the financial	Share	
	instrument, type of instrument		
	Identification code	DK0010272202	
b)	Nature of the transaction	Acquisition due to vesting of restricted	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	247
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	2023-01-02	
f)	Place of the transaction	Outside a market place	

#### About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 11/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122



#### Contact:

Marisol Peron, Senior Vice President, Communications and Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; Genmab in combination with the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; DuoBody<sup>®</sup>; DuoBody in combination with the DuoBody logo<sup>®</sup>; HexaBody<sup>®</sup>; HexaBody in combination with the HexaBody logo<sup>®</sup>; DuoHexaBody<sup>®</sup> and HexElect<sup>®</sup>.

Genmab A/S Kalvebod Brygge 43 21560 Copenhagen V, Denmark Tel: +45 7020 2728 Fax: +45 7020 2729 www.genmab.com Company Announcement no. 01 Page 12/12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122